CMAC’s vision is to revolutionise the way pharmaceuticals and high value products are made. The approaches developed and adopted within CMAC have been developed through close collaboration with industry and the support of its Tier 1 partners, which includes GlaxoSmithKline, AstraZeneca, Bayer, Lilly, Novartis, Pfizer, Roche and Takeda. Established in 2011, the CMAC has a £150m funding portfolio and currently comprises more than 130 staff and researchers, including academics, post docs, and more than 45 PhD students, as well as an experienced support team.
Accelerating the delivery of new drugs to patients
A project aimed at accelerating the delivery of new drugs to patients, led by the University of Strathclyde and Glasgow School of Art, has received a grant of £1.9 million..... more
Strathclyde in Medicines Manufacturing Innovation Centre
The University of Strathclyde is a strategic partner in a new £56 million UK innovation centre, which will revolutionise the way medicines are manufactured..... more
Chemical Engineer Article May 2018
"Continuous crystallisation workflow enables high precision manufacturing of pharmaceuticals" Article by Amanda Doyle.... more